

AUTHOR INDEX
Volume 37
January-June, 1988

- Abercrombie, B., 425
 Agarwal, A., 301
 Agarwal, K., 99
 Agback, H., 539
 Alcalay, R., 383
 Amatayakul, K., 483
 Aulitzky, W., 153
 Bachorik, P.S., 39
 Bajpai, V.K., 99
 Baras, M., 607
 Bardin, C.W., 539
 Barker, D., 577
 Barratt, C.L.R., 415
 Beaudoin, A.R., 197
 Belenguer, A., 229
 Benavides, S., 591
 Benz, C., 221
 Bhowmik, T., 529
 Brookes, A.N., 229
 Brown-Woodman, P.D., 269
 Burkman, R.T., 21, 39
 Cai, W-j, 129
 Cao, J., 111
 Cárdenas, H., 85
 Cecchetti, G., 29
 Chen, K.-Q., 257
 Chen, Z-W, 119
 Ch'iu-Hinton, K., 111
 Cimber, H., 503
 Cohen, J., 415
 Corin, R.E., 247
 Coutinho, E., 137
 Croxatto, H.B., 85
 Das, R.P., 631
 Das, S., 371
 Dash, D.S., 371
 Desager, J.P., 565
 Dhall, K., 75
 Díaz-Sánchez, V., 349, 471, 591
 Didolkar, A.K., 539
 Dieu, J.P., 173
 Ding, J-H, 119
 Dogra, M., 75
 Dong, C-j, 129
 Dreher, E., 503
 Fasoli, M., 29
 Fei, R.R., 279, 291
 Fotherby, K., 359, 517
 Frick, J., 153
 Gao, Z-q, 129
 Garza-Flores, J., 349, 471, 591
 Gaspard, U., 565
 Gleicher, N., 391
 Gold, E.B., 21, 39
 Goldberg, H., 221
 Gordon, L., 607
 Griffin, M., 53
 Haider, S.G., 257
 Harlap, S., 607
 Harvengt, C., 565
 Haspel, H.C., 247
 He, C-h, 359
 Heaton, D.A., 53
 Heywood, R., 185
 Hoffer, A.P., 247, 301
 Hoppe, G., 493
 Hu, Y-Z, 119
 Hu, Z-Z, 517
 Huang, J.-T., 247
 Jaffe, B., 607
 Jimenez-Thomas, S., 471
 Johansson, E.D.B., 61, 539
 Jung, J., 349
 Kalla, N.R., 153
 Keizer-Zucker, A., 539
 Keniry, M., 221
 Ketting, E., 343
 Kimball, A.W., 39
 Kjaergaard, B., 621
 Kjaergaard, N., 621
 Klaus, H., 577
 Klein, T.A., 405
 Koide, S.S., 333
 Kruszon-Moran, D., 39
 Kwan, M., 599
 Labbok, M.H., 577
 Lauritsen, J.G., 621
 La Vecchia, C., 29
 Lepot, M., 565
 Letterie, G.S., 405
 Li, B., 111
 Li, H-z, 163
 Li, J-Z, 517
 Lieblich, A., 607
 Lin, X.d., 239
 Liu, A-R, 517
 Liu, G-z, 111
 Liu, J-L, 517

CONTRACEPTION

- Luo, H-z, 163
- Machin, D., 119
- Madanes, A., 391
- Magidor, S., 607
- Majumdar, S.S., 631
- Mall-Haefeli, M., 503
- Marbaix, E., 173
- Mason, K.J., 21
- Matlin, S.A., 229, 301
- McEwan, J.A., 53
- Melo, J.F., 137
- Meltzer, P., 301
- Meng, G-D, 119
- Mezzanotte, G., 29
- Mitchell, J., 383
- Moore, G.D., 85
- Muhlemann, M., 503
- Mukherjea, M., 529
- Nanda, U., 371
- Nagvi, R., 301
- Odland, V., 61
- Olsson, S-E, 61
- Oropeza, G., 591
- Parazzini, F., 29
- Percival-Smith, R.K.L., 425
- Pérez-Palacios, G., 349, 591
- Petpoo, W., 483
- Pinol, A., 119
- Qian, S-Z, 119
- Rapkin, A.J., 383
- Ratanawanankul, N., 483
- Ratnam, S.S., 457
- Recio, R., 591
- Ren, Y.-F., 247
- Roke, C.M., 555
- Ryan, E.A., 549
- Sahni, M.K., 333
- Salazar, A., 85
- Salomón-Andoníe, J., 471
- Samal, K.C., 371
- Sanchez, M., 607
- Sar, M., 257
- Schiavon, R., 591
- Segal, S.J., 333
- Sethi, N., 99
- Sharma, R.K., 631
- Shi, Y-e, 359
- Singh, K., 457
- Singh, R.K., 99
- Sivin, I., 61
- Sonenberg, M., 247
- Stumpf, W.E., 257
- Su, T.-L., 247
- Sundaram, K., 539
- Suriyanon, V., 483
- Swan, M.A., 269
- Tan, Y-b, 191
- Tang, G.W.K., 599
- Tanthayaphinant, O., 483
- Teng, C.S., 279, 291
- Toder, V., 391
- Toth, E.L., 549
- Tovanabutra, S., 483
- Tripathy, B.B., 371
- Tyson, R.G., 229
- U.S. Food and Drug Adminis-
tration, 433
- Ueno, H., 333
- van Ypersele de Strihou, C., 173
- Viegas, O.A.C., 457
- Vishwanath, R., 269
- Waites, G.M.H., 119
- Wang, C., 119
- Wang, R-l, 191
- Wang, X-H, 119
- Watanabe, K.A., 247
- White, I.G., 269
- WHO Task Force on Long-Acting
Systemic Agents for Fertility
Regulation, 1
- Winkel, C.A., 405
- Wong, L-T, 119
- Wu, J-H, 517
- Wu, S-X, 517
- Xu, D., 129
- Xu, G-X, 517
- Xue, S-p, 163, 257
- Yáñez, L., 349
- Yin, B-Y, 517
- Yu, A.F., 517
- Yu, P-p, 359
- Zhang, G-Y, 119
- Zhang, Z-s, 191
- Zhao, S-y, 163
- Zheng, S-h, 359
- Zheng, Z-c, 129
- Zhou, R.h., 239
- Zhou, R.H., 229
- Zhu, B-h, 129
- Zhu, C., 111
- Zhu, J-b, 163
- Zhu, J-C, 119
- Zhu, Y-h, 359

SUBJECT INDEX

VOLUME 37

January to June 1988

- Abortion, risk of subsequent ectopic pregnancy, 21
- Acceptability, non-surgical sterilization using
phenol-mucilage, 599
- Accessory sex gland function, effect of STS 557
(monkey), 631
- Acid phosphatase level, effect of gossypol, 119
- Administration of oral contraceptives, 433
- Adrenal cortical function and its reserve capacity,
use of depot-medroxyprogesterone acetate, 483
use of norethisterone enanthate, 483
- Adverse reactions, use of oral contraceptives, 433
- Alcohol consumption and oral contraceptive use, effect on
lipids and lipoproteins, 39
- p-Aminobenzamidine, effect of intrauterine administration
on reproductive function (rat), 85
- Antifertility activity,
gossypol (rat), 269
gossypol analogues (hamster), 247
sulfasalazine and derivatives (rat), 539
- Antifertility effects, gossypol and derivatives (rat,
hamster), 301
- Antiproliferative activity, effect of gossypol, 221
- Antitumor toxicity, gossypol, 221
- Apolipoprotein-A1 level, interaction of alcohol consumption
and oral contraceptive use, 39
- ATP production and utilization, effect of gossypol, 333
- Autoradiography, distribution of gossypol (rat), 257
- Banjauri (*Vicco Indica*), contraceptive efficacy, 75
- Behavioral studies of offspring, effect of gossypol
(rat), 197
- Bioavailability, norethisterone in different
formulations, 349
- Biochemical effects, gossypol (monkey), 185
- Biochemical parameters, effect of *Vicco Indica*
(Banjauri), 75
- Biological activities, gossypol analogues, 247
- Birth defects risk, use of oral contraceptives, 433
- Bleeding irregularities, use of oral contraceptives, 433

CONTRACEPTION

- Bleeding pattern,
 - effect of estradiol cypionate + depot-medroxyprogesterone acetate, 1
 - effect of estradiol enanthate + dihydroxyprogesterone acetophenide, 591
 - effect of estradiol valerate + norethisterone enantate, 1
 - effect of ethinylestradiol + gestoden, 493
 - effect of levonorgestrel, 61, 457
 - effect of mestranol + norethisterone, 471
- Blood pressure,
 - effect of estradiol cypionate + depot-medroxyprogesterone acetate, 1
 - effect of estradiol valerate + norethisterone enantate, 1
 - effect of ethinylestradiol + gestoden, 493
 - effect of levonorgestrel, 61, 457
 - use of oral contraceptives, 433
- Body and organ weights, effect of sulfasalazine and derivatives (rat), 539
- Bone marrow cell, effect of gossypol (mouse), 191
- Bone marrow stem cells, effect of gossypol, 221
- Carbohydrate metabolism,
 - effect of ethinylestradiol + norethisterone, 517
 - effect of norethisterone oenanthate, 53
 - effect of quinestrol + 16-methylene chlormadinone acetate, 517
 - effect of use of oral contraceptives, 433
- Carcinoma of reproductive organs, use of oral contraceptives, 433
- Cell membrane, effect of gossypol, 179
- Characteristics, women who request postcoital contraception, 425
- Cholesterol level, effect of levonorgestrel, 371
- Cholesterol metabolism, effect of ethinyl estradiol and norgestrel (rat), 405
- Chromosomal basic protein syntheses, effects of gossypol (rat), 291
- Clinical chemistry determinations,
 - effect of gossypol, 137, 153
 - effect of gossypol (dog), 173
- Clinical effects, gossypol (monkey), 185
- Clinical experience, use of gossypol, 137
- Clinical pharmacology, combination oral contraceptives, 433
- Clinical safety, use of gossypol, 129
- Clinical study, gossypol microdose, 153
- Combination oral contraceptives,
 - labeling guidance text, 433
 - reliability, 343
- Complications, non-surgical sterilization using phenol-mucilage, 599
- Contraceptive choice, result of non-availability of IUD, 383
- Contraceptive effect, IUD action (mouse), 391

- Contraceptive efficacy,
 - estradiol cypionate + depot-medroxyprogesterone acetate, 1
 - estradiol valerate + norethisterone enantate, 1
 - Vicoa Indica (Banjauri), 75
- Contraindications, use of oral contraceptives, 433
- Copper 7, rate of ease of removal, 555
- Copper T, rate of ease of removal, 555
- Cortisol excretion,
 - use of depot-medroxyprogesterone acetate, 483
 - use of norethisterone enanthate, 483
- Cortisol level,
 - effect of ethynylestradiol + norethisterone, 517
 - effect of quinestrol + 16-methylene chlormadinone acetate, 517
- Cortisol response to insulin-induced hypoglycaemia, injectable contraceptive users, 483
- Cytocidal assay, effect of gossypol analogues (mouse, hamster), 247
- Developmental toxicity evaluation, gossypol (rat), 197
- Discontinuation,
 - use of estradiol cypionate + depot-medroxyprogesterone acetate, 1
 - use of estradiol valerate + norethisterone enantate, 1
 - use of ethinylestradiol + gestoden, 493
 - use of Vicoa Indica (Banjauri), 75
- Dissatisfaction with contraceptive method, result of non-availability of IUD, 383
- Early development, effect of medroxyprogesterone acetate on progeny, 607
- Ectopic pregnancy,
 - effect of maternal age, 29
 - effect of prior induced abortion, 21
 - effect of use of IUDs, 29
- Enantiomers of gossypol, large-scale resolution for biological evaluation, 229
- Endometrium, effect of levonorgestrel IUD (monkey), 99
- Enzyme histochemistry, effects of gossypol (rat), 257
- Enzyme systems of sperm, interaction of gossypol, 333
- Erythrocyte membrane functions, effect of gossypol, 179
- Estradiol cypionate + depot-medroxyprogesterone acetate, contraceptive efficacy and side effects, 1
- Estradiol enanthate + dihydroxyprogesterone acetophenide,
 - effect on estrogens profile, 591
 - ovulation return, 591

CONTRACEPTION

- Estradiol level,
 - effect of estradiol enanthate + dihydroxyprogesterone acetophenide, 591
 - effect of ethynylestradiol + norethisterone, 517
 - effect of levonorgestrel, 359
 - effect of mestranol + norethisterone, 471
 - effect of quinestrol + 16-methylene chlormadinone acetate, 517
- Estradiol valerate + norethisterone enantate, contraceptive efficacy and side effects, 1
- Estrone level, effect of estradiol enanthate + dihydroxyprogesterone acetophenide, 591
- Ethinyl estradiol, effect on hepatic cholesterol metabolism (rat), 405
- Ethinylestradiol + desogestrel, effect on lipid and lipoprotein metabolism, 565
- Ethinyl estradiol + ethynodiol diacetate, interaction of alcohol consumption on lipids and lipoproteins, 39
- Ethinylestradiol + gestoden, clinical trial, 493
- Ethinylestradiol + levonorgestrel,
 - effect on lipid and lipoprotein metabolism, 565
 - interaction of alcohol consumption on lipids and lipoproteins, 39
- Ethinyl estradiol + norethindrone,
 - interaction of alcohol consumption on lipids and lipoproteins, 39
 - metabolic effects, 549
- Ethinyl estradiol + norgestrel, effect on hepatic cholesterol metabolism (rat), 405
- Ethinyl estradiol + dl-norgestrel, use as postcoital contraception, 425
- Ethinylestradiol + norethisterone,
 - metabolic changes, 517
 - return of ovulation on discontinuation, 517
- Factors related to Ovulation Method efficacy, 577
- Failure, oral contraceptive pills, 343
- Fallopian tubes, effect of levonorgestrel IUD (monkey), 99
- Fertility,
 - effect of gossypol (hamster), 229
 - effect of gossypol (rat), 197, 301
 - effect of gossypol and derivatives (hamster), 301
- Fertilization,
 - effect of gossypol, 333
 - effect of intrauterine administration of gossypol, nonoxynol-9 or p-aminobenzamidine (rat), 85
- FSH (follicle stimulating hormone)
- FSH level,
 - effect of gossypol, 119, 153
 - effect of levonorgestrel, 359
- Gallbladder diseases, use of oral contraceptives, 433
- Genotoxic effects, gossypol (mouse), 191
- Gestoden, an innovative progestogen, 493

- Glucose tolerance test,
 - effect of ethinyl estradiol + norethindrone, 549
 - effect of norethisterone oenanthate, 53
- Gossypol,
 - antifertility activity (rat), 269
 - antitumor toxicity, 221
 - autoradiography study (rat), 257
 - clinical experience, 137
 - clinical safety, 129
 - clinical study, 153
 - developmental toxicity evaluation (rat), 197
 - effect of intrauterine administration on reproductive function (rat), 85
 - effect of K salt or potassium blocker on hypokalemia, 111
 - effect on activity of kidney ($\text{Na}^+ + \text{K}^+$)-ATPase, 179
 - effect on functions of erythrocyte membrane, 179
 - effect on hormone and semen acid phosphatase values, 119
 - effect on kidney (dog), 173
 - effect on nuclear proteins in testes (rat), 279, 291
 - effect on testicular function (rat), 257
 - enzyme histochemistry study (rat), 257
 - genotoxic effects (mouse), 191
 - interaction with sperm macromolecules and enzymes, 333
 - large-scale resolution of enantiomers, 229
 - recovery of spermatogenesis after cessation of treatment, 119
 - renal tubulo-toxic effect (rat, guinea pig), 163
 - toxicology (rat, monkey), 185
- (-)-Gossypol, isolation from natural plant, 239
- Gossypol analogues, biological activities, 247
- Gossypol and derivatives, antifertility, spermicidal and ultrastructural effects (rat, hamster), 301
- Headache, use of oral contraceptives, 433
- Health benefits, non-contraceptive, use of oral contraceptives, 433
- Hematological factors,
 - effect of ethynylestradiol + norethisterone, 517
 - effect of quinestrol + 16-methylene chlormadinone acetate, 517
- Hematological parameters, effect of *Vicoa Indica* (Banjauri), 75
- Hemoglobin level, effect of levonorgestrel, 61
- Hepatic cholesterol metabolism, effect of ethinyl estradiol and norgestrel (rat), 405
- Hepatic neoplasia, use of oral contraceptives, 433
- Herbal contraceptive, *Vicoa Indica* (Banjauri), 75
- Hormone levels, effect of gossypol, 153
- Hypokalemia caused by gossypol treatment, effects of K salt or potassium blocker, 111
- Immune function, effect of gossypol, 129
- Immunologic aspects, IUD action (mouse), 391

CONTRACEPTION

- Implant contraceptive, levonorgestrel, 61, 371, 457
- Implantation, effect of intrauterine administration of gossypol, nonoxynol-9 or p-aminobenzamidine (rat), 85
- Induced abortion, risk of subsequent ectopic pregnancy, 21
- Injectable contraceptive,
 - depot-medroxyprogesterone acetate, 483
 - depot-norethisterone oenanthate, 53
 - estradiol cypionate + depot-medroxyprogesterone acetate, 1
 - estradiol enanthate + dihydroxyprogesterone acetophenide, 591
 - estradiol valerate + norethisterone enantate, 1
 - mestranol + norethisterone, 471
 - norethisterone enanthate, 483
- Insulin level,
 - effect of ethinyl estradiol + norethindrone, 549
 - effect of norethisterone oenanthate, 53
- Insulin-induced hypoglycaemia, response in injectable contraceptive users, 483
- Intellectual development, effects of medroxyprogesterone acetate on progeny, 607
- Intrauterine device (IUD),
 - copper 7, 555
 - copper T, 555
 - Lippes loop, 555
 - Multiload copper 250, 555
 - non-availability and contraceptive choice, 383
 - Nova T, 555
 - Saf-T-Coil, 555
- Intrauterine occlusion body,
 - clinical trial, 503
 - functions and properties, 503
- IUD (intrauterine device)
- IUD action, immunologic aspects (mouse), 391
- IUD removal, comparative study of various devices, 555
- IUD use, relative risk of ectopic pregnancy, 29
- K salt and potassium blocker, effects on gossypol-related hypokalemia, 111
- K⁺ transport, effect of gossypol, 179
- Kidney (Na⁺ + K⁺)-ATPase activity, effect of gossypol, 179
- Labeling guidance text, combination oral contraceptives, 433
- Levonorgestrel,
 - clinical experience, 457
 - clinical study, 61
 - effect on lipid profile, 371
 - pharmacokinetics, 359
 - use as postcoital contraceptive, 359
- Levonorgestrel IUD, effect on uterine endometrium (monkey), 99
- Levonorgestrel level, administration of levonorgestrel, 359
- LH (luteinizing hormone)

- LH level,
 - effect of gossypol, 119, 153
 - effect of levonorgestrel, 359
- LHRH (luteinizing hormone releasing hormone)
 - LHRH response, effect of gossypol, 137
- Lipid and protein levels,
 - effect of ethinyl estradiol + desogestrel, 565
 - effect of ethinyl estradiol + levonorgestrel, 565
 - interaction of alcohol consumption and oral contraceptive use, 39
- Lipid metabolism, effect of use of oral contraceptives, 433
- Lipid parameters, effect of oral contraceptives, 39
- Lipid profile, effect of levonorgestrel, 371
- Lipids,
 - effect of ethinyl estradiol + norethindrone, 549
 - effect of ethinylestradiol + norethisterone, 517
 - effect of quinestrol + 16-methylene chlormadinone acetate, 517
- Lipids level, effect of gossypol, 129
- Lippes loop, rate of ease of removal, 555
- Liver function, effect of gossypol, 129
- Long-term effect of medroxyprogesterone acetate,
 - intellectual development of offspring, 607
- Macrocrystalline aqueous suspension, mestranol + norethisterone, 471
- Macromolecules and enzymes of sperm, interaction of gossypol, 333
- Magnetic resonance spectroscopy, monitoring of gossypol antitumor toxicity, 221
- Male antifertility activity, sulfasalazine and derivatives (rat), 539
- Male contraceptive,
 - Prazosin, 621
 - STS 557 (monkey), 631
- Malformations in fetuses, effect of gossypol (rat), 197
- Manganese, effect on gossypol action (ram), 269
- Maternal age, relative risk of ectopic pregnancy, 29
- Mechanism of action, gossypol (ram), 269
- Medroxyprogesterone acetate,
 - effect on adrenal function and its reserve capacity, 483
 - effect on intellectual development of progeny, 607
 - effect on ovary and uterus (rat), 529
- Menstrual cycle, effect of ethinylestradiol + gestoden, 493
- Mestranol + norethisterone, macrocrystalline aqueous suspension, clinical assessment, 471
- Metabolic changes,
 - use of ethinyl estradiol + norethindrone, 549
 - use of ethinylestradiol + norethisterone, 517
 - use of quinestrol + 16-methylene chlormadinone acetate, 517
- Mononuclear cell population of uterine cavity, IUD action (mouse), 391
- Morphological effects, gossypol (rat), 301

CONTRACEPTION

- Mortality rates, users of methods of contraception, 433
- Motor apparatus of sperm, effect of gossypol (ram), 269
- Multiload copper 250, rate of ease of removal, 555
- Natural family planning, efficacy of Ovulation Method, 577
- Natural source of (-)-gossypol, 239
- Non-availability of IUD and contraceptive choice, 383
- Non-contraceptive health benefits, use of oral contraceptives, 433
- Nonoxynol-9, effect of intrauterine administration on reproductive function (rat), 85
- Norethisterone, bioavailability and pharmacokinetics, 349
- Norethisterone enanthate,
 - effect on adrenal function and its reserve capacity, 483
 - effect on carbohydrate metabolism, 53
 - effect on ovary and uterus (rat), 529
- Norethisterone level,
 - administration of norethisterone in different formulations, 349
 - following administration of mestranol + norethisterone, 471
- Norethisterone-cholesterol eutectic mixture, bioequivalence study, 349
- Norgestrel, effect on hepatic cholesterol metabolism (rat), 405
- Norplant^R,
 - clinical experience, 457
 - clinical study, 61
- Norplant^R-2,
 - clinical study, 61
 - lipid profile study, 371
- Nova T, rate of ease of removal, 555
- Nuclear proteins in testes, effects of gossypol (rat), 279, 291
- Ocular lesions, use of oral contraceptives, 433
- Optical activity, gossypol in cottonseed of different species, 239
- Oral contraceptive,
 - ethinylestradiol + desogestrel, 565
 - ethinyl estradiol + ethynodiol diacetate, 39
 - ethinylestradiol + gestoden, 493
 - ethinyl estradiol + levonorgestrel, 39, 565
 - ethinyl estradiol + norethindrone, 39, 549
 - ethinylestradiol + norethisterone, 517
 - norethisterone, 349
 - norethisterone-cholesterol eutectic mixture, 349
 - quinestrol + 16-methylene chlormadinone acetate, 517
 - relative reliability, 343
 - revised physicians' package insert text, 433
- Oral contraceptive use and alcohol consumption, effect on lipids and lipoproteins, 39
- Ovarian function, effect of mestranol + norethisterone, 471

- Ovary,
 - effect of levonorgestrel IUD (monkey), 99
 - histological changes after depo-medroxyprogesterone acetate (rat), 529
 - histological changes after norethisterone enanthate (rat), 529
- Overdosage, use of oral contraceptives, 433
- Ovulation Method,
 - factors related to efficacy, 577
 - natural family planning, 577
 - pregnancy rates, 577
- Ovulation on discontinuation,
 - use of ethynylestradiol + norethisterone, 517
 - use of quinestrol + 16-methylene chlormadinone acetate, 517
- Ovulation return, effect of estradiol enanthate + dihydroxyprogesterone acetophenide, 591
- Pathological effects, gossypol (monkey), 185
- Pharmacokinetic parameters, norethisterone, 471
- Pharmacokinetics,
 - levonorgestrel, 359
 - norethisterone in different formulations, 349
- Phenol-mucilage, non-surgical sterilization, 599
- Postcoital contraception, characteristics of women who use method, 425
- Postcoital contraceptive,
 - ethinyl estradiol + dl-norgestrel, 425
 - levonorgestrel, 359
- Potassium level,
 - effect of gossypol, 129, 137, 153
 - effect of gossypol (dog), 173
 - effect of gossypol (rat, guinea pig), 163
- Prazosin, efficacy and acceptability as male contraceptive, 621
- Precautions, use of oral contraceptives, 433
- Pregnancy, following non-surgical sterilization using phenol-mucilage, 599
- Pregnancy outcome, effect of gossypol (rat), 197
- Pregnancy rate,
 - Ovulation Method, 577
 - use of levonorgestrel, 61
 - users of methods of contraception, 433
- Progeny exposed to medroxyprogesterone acetate in utero, intellectual development, 607
- Progesterone level,
 - effect of ethynylestradiol + norethisterone, 517
 - effect of levonorgestrel, 359
 - effect of mestranol + norethisterone, 471
 - effect of quinestrol + 16-methylene chlormadinone acetate, 517
- Prolactin level, effect of levonorgestrel, 359
- Protein phosphorylation, effect of gossypol, 333

CONTRACEPTION

- Quinestrol + 16-methylene chlormadinone acetate,
 - metabolic changes, 517
 - return of ovulation on discontinuation, 517
- Recovery rate, after cessation of gossypol treatment, 119
- Relative reliability, oral contraceptives, 343
- Relative risk,
 - ectopic pregnancy following prior induced abortion, 21
 - ectopic pregnancy in relation to IUD use, 29
- Removal of IUD, comparative study of various devices, 555
- Removal rate, use of intrauterine occlusion body, 503
- Renal function, effect of gossypol, 129, 153
- Renal toxicity study, gossypol (dog), 173
- Renal tubulo-toxic effect, gossypol (rat, guinea pig), 163
- Resolution of gossypol enantiomers for biological evaluation, 229
- Return of ovulation on discontinuation,
 - use of ethynylestradiol + norethisterone, 517
 - use of quinestrol + 16-methylene chlormadinone acetate, 517
- Saf, T-Coil, rate of ease of removal, 555
- Semen volume, effect of Prazosin, 621
- Sequential oral contraceptives, reliability, 343
- Side effects,
 - use of estradiol cypionate + depot-medroxyprogesterone acetate, 1
 - use of estradiol valerate + norethisterone enantate, 1
 - use of ethinylestradiol + gestoden, 493
 - use of gossypol, 129
 - use of intrauterine occlusion body, 503
 - use of levonorgestrel, 61, 457
 - use of Prazosin, 621
- Skeletal development of fetuses, effect of gossypol (rat), 197
- Spatial ability, effect of medroxyprogesterone acetate on progeny, 607
- Sperm,
 - effect of gossypol (rat), 269
 - mechanism of action of gossypol (ram), 269
- Sperm count,
 - effect of gossypol, 129, 137, 153
 - effect of Prazosin, 621
 - effect of STS 557 (monkey), 631
 - effect of sulfasalazine and derivatives (rat), 539
- Sperm enzymes, effect of STS 557 (monkey), 631
- Sperm macromolecules and enzymes, interaction of gossypol, 333
- Sperm migration, effect of intrauterine administration of gossypol, nonoxynol-9 or p-aminobenzamidine (rat), 85
- Sperm morphology, effect of STS 557 (monkey), 631

- Sperm motility,
 - effect of gossypol, 137, 153
 - effect of gossypol analogues (hamster), 247
 - effect of gossypol and derivatives, 301
 - effect of Prazosin, 621
 - effect of STS 557 (monkey), 631
 - effect of sulfasalazine and derivatives (rat), 539
- Sperm transport, effect of vasectomy (mouse), 415
- Spermatogenesis,
 - effect of vasectomy (mouse), 415
 - recovery after cessation of gossypol treatment, 119
- Spermatogonia, effect of gossypol (mouse), 191
- Spermicidal activity, gossypol analogues (hamster), 247
- Spermicidal effects, gossypol and derivatives (hamster), 301
- Spermio-genic cells, effect of gossypol (rat), 279, 291
- Sterilization, non-surgical use of phenol-mucilage, 599
- STS 557 (17 α -cyanomethyl-17 β -hydroxy-estra-4,9(10)-diene-3-one), effects on semen and sperm functions (monkey), 631
- Sulfasalazine and derivatives, effect on fertility (rat), 539
- Synthesis of chromosomal basic proteins, effects of gossypol (rat) 291
- Terminations, use of levonorgestrel, 61, 457
- Testicular functions, effect of gossypol (rat), 257
- Testis,
 - effect of gossypol, 119
 - effect of gossypol (rat), 269, 301
 - effect of gossypol analogues (rat), 247
 - effect of gossypol and derivatives (hamster), 301
 - effect of gossypol on nuclear proteins (rat), 279, 291
 - effect of vasectomy (mouse), 415
- Testosterone level,
 - effect of gossypol 119, 129, 137, 153
 - effect of gossypol (rat), 269
 - effect of STS 557 (monkey), 631
- Thromboembolic disorders and other vascular problems,
 - use of oral contraceptives, 433
- Total nuclear basic proteins of spermatids, effect of gossypol (rat), 279, 291
- Toxicity, gossypol, 221
- Toxicology, gossypol (rat, monkey), 185
- Triamterene, effects on gossypol-related hypokalemia, 111
- Triglycerides level,
 - effect of levonorgestrel, 371
 - interaction of alcohol consumption and oral contraceptive use, 39
- Triphasic oral contraceptives, reliability, 343
- Tubal occlusion, use of intrauterine occlusion body, 503
- Tubal occlusion agent, phenol-mucilage, 599
- Ultrastructural effects,
 - gossypol (rat), 301
 - gossypol and derivatives (hamster), 301

CONTRACEPTION

- Urinary protein analysis,
 - effect of gentamicin (rat, guinea pig), 163
 - effect of gossypol (rat, guinea pig), 163
- User satisfaction, use of levonorgestrel implants, 457
- Uterus,
 - histological changes after depo-medroxyprogesterone acetate (rat), 529
 - histological changes after norethisterone enanthate (rat), 529
 - IUD action (mouse), 391
- Varicocele, use of gossypol, 137
- Vasectomy, effect of testes (mouse), 415
- Verbal ability, effect of medroxyprogesterone acetate on progeny, 607
- Vicco Indica (Banjauri),
 - clinical trial, 75
 - herbal contraceptive, 75
- Weight,
 - effect of estradiol cypionate + depot-medroxyprogesterone acetate, 1
 - effect of estradiol valerate + norethisterone enanthate, 1
 - effect of ethinylestradiol + gestoden, 493
 - effect of gossypol (rat), 185, 197, 269
 - effect of levonorgestrel, 61, 457
- Zona-free hamster egg penetration assay, effect of STS 557 (monkey), 631

